GuideNephrology
COVID-19 and the kidney: acute kidney injury and antiviral dosing
Summary of kidney involvement in SARS-CoV-2 infection (frequency, mechanisms, prognosis) and of the kidney-related considerations of current treatment.
Updated 3 November 2026
When to use it
In patients with COVID-19 who are hospitalised, have chronic kidney disease, are on dialysis or have a kidney transplant, to prevent, detect and manage kidney injury.
Warning
The original 2020 document is outdated. This sheet summarises the evidence and current CDC recommendations as of November 2026; antiviral labels change: check them before prescribing.
Frequency and prognosis
During the first wave in New York (5,449 hospitalised adults, 2020), 36.6% developed AKI and 14.3% of these needed dialysis. AKI was associated mainly with mechanical ventilation (89.7% of ventilated patients) and with poor prognosis. With current variants, vaccination and antivirals, severe COVID-19 and AKI are much less common.
Keep reading in the app
- Mechanisms
- Management
- Antivirals and kidney function (current)
Practical tip
COVID-19-associated AKI is diagnosed and staged with standard KDIGO criteria and managed like other AKI: there is no kidney-specific treatment.
2 more practical tips in the app.
Reference
- Nadim MK, Forni LG, Mehta RL, Connor MJ Jr, Liu KD, Ostermann M, et al. COVID-19-associated acute kidney injury: consensus report of the 25th Acute Disease Quality Initiative (ADQI) Workgroup. Nat Rev Nephrol. 2020;16(12):747-764.
- Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209-218.
- Centers for Disease Control and Prevention. Clinical Considerations for Outpatient Treatment of COVID-19 (updated 8 Oct 2026).
Official source: CDC: outpatient treatment of COVID-19
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
